Soluble Receptors for Cytokines and Growth Factors

Müller‐Newen, Gerhard; Köhne, Christian; Heinrich, Peter C.

doi:10.1159/000237353

Cited by 30 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surface expression of other transmembrane receptors can be regulated by proteolytic cleavage (Arend, 1995;Muller-Newen et al, 1996;Heaney and Golde, 1998;Peschon et al, 1998;Fernandez-Botran, 1999) or altered trafficking and/or processing (Kozarsky et al, 1988;Altschuler et al, 2000;Zhao et al, 2001). While soluble C1qR P /CD93 has not been detected in the serum of normal patients (Nepomuceno and Tenner, unpublished observations), sera from patients have not been tested, and thus decreased C1qR P /CD93 expression and the presence of soluble C1qR P /CD93 in certain pathological conditions remains to be investigated.…”

Section: Discussionmentioning

confidence: 99%

Cell surface expression of C1qR_P/CD93 is stabilized by O‐glycosylation

Park

Tenner

2003

Journal Cellular Physiology

View full text Add to dashboard Cite

C1qRP/CD93 is a cell surface receptor predominantly expressed on monocytes, neutrophils, endothelial cells, and early stem cell precursors. In phagocytic cells, it has been characterized as contributing to the enhancement of FcR- and CR1-induced phagocytosis triggered by innate immune system defense collagens such as C1q and mannose binding lectin (MBL). Previously, we demonstrated a high level of glycosylation on C1qRP/CD93 that was predominantly O-linked. In this study, we investigate the role of glycosylation in C1qRP/CD93 stability first by inhibiting O-glycosylation by addition of benzyl 2-acetamido-2-deoxy-alpha-D-galactopyranoside (BAG) to the human histiocytic cell line U937, and secondly, by expression of C1qRP/CD93 in the CHO-derived cell line ldlD which has a reversible defect in protein glycosylation. In both U937 cells and in ldlD cells transfected to express C1qRP/CD93, glycosylation deficiency caused cell surface expression levels of C1qRP/CD93 to decrease, concomitant with the detection of C1qRP/CD93 reactivity in the culture media. Metabolic labeling studies show that when glycosylation is absent, C1qRP/CD93 is synthesized and rapidly released into the culture supernatant or degraded. These studies demonstrate that O-glycosylation is important in the stable cell surface expression of C1qRP/CD93 .

show abstract

Section: Discussionmentioning

confidence: 99%

Cell surface expression of C1qR_P/CD93 is stabilized by O‐glycosylation

Park

Tenner

2003

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…sCD25 binds IL-2 with much less avidity than does the intact three-chain receptor on the cell surface [13]. Soluble cytokine receptors may act as antagonists by binding the ligand and neutralising its biological activity 9 Alternatively, they may constitute a depot for cytokines because the complexes are cleared from the circulation at a reduced rate relative to the free ligands [14]. Although the relatively low affinity of sCD25 for IL-2 might be expected to impair its ability to act as an IL-2 antagonist in vivo, high concentrations of purified sCD25 specifically inhibit IL-2R activity in vitro [15].…”

Section: Discussionmentioning

confidence: 99%

Relations between surface expression of the interleukin-2 receptor and release of the soluble form of the receptor in cultured mononuclear cells from patients with rheumatoid arthritis or systemic lupus erythematosus

et al. 1998

View full text Add to dashboard Cite

The relationship between surface expression of the interleukin-2 receptor (IL-2R) and release of the soluble form of the receptor (sIL-2Ralpha or sCD25) was investigated with peripheral blood mononuclear cells (PBMCs) from individuals with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). The spontaneous release of sCD25 was significantly increased in PBMCs from RA patients and decreased in cells from SLE patients, compared with normal controls. However, the extent of sCD25 release from phytohaemagglutinin (PHA)-stimulated PBMCs did not differ between RA or SLE patients and normal controls. The serum concentration of sCD25 was significantly increased in SLE or RA patients compared with the normal controls. Whereas the surface expression of CD25 by unstimulated PBMCs did not differ among the three groups of subjects, this parameter was significantly reduced for PHA-stimulated PBMCs from RA patients relative to those from normal controls. The surface expression of CD25 showed a positive correlation with sCD25 release for PBMCs from SLE patients under either basal or stimulated conditions. No such relation was apparent for cells from RA patients. The surface expression of IL-2Rbeta (CD 122) under basal or stimulated conditions was significantly reduced in PBMCs from RA or SLE patients, compared with cells from normal controls. Thus, the increased concentration of sCD25 in the serum of individuals with these autoimmune rheumatic diseases may result from two different mechanisms: an increase in the spontaneous release of sCD25 in RA, and reduced clearance of this protein in SLE.

show abstract

“…We have demonstrated a correlation between both TNF receptor serum levels and prognosis (univariate analysis) and found, additionally, the TNF RII serum level plays an independent role as a prognostic factor in soft tissue sarcoma patients without metastases. Soluble cytokine receptors are released from the surface of activated normal and neoplastic cells through shedding or splicing and function usually as cytokine antagonists, 64 although some cytokine-receptor complexes may act agonistically with the respective ligands. 65 Increased concentration of soluble forms of cell surface proteins is a common tendency in malignancy.…”

Section: Cytokine Serum Levels During Follow-upmentioning

confidence: 99%

Cytokine serum levels in soft tissue sarcoma patients: Correlations with clinico‐pathological features and prognosis

Rutkowski

Kamińska

Kowalska

et al. 2002

Intl Journal of Cancer

View full text Add to dashboard Cite

We investigated the correlations between serum levels of selected proinflammatory, hematopoietic and angiogenic cytokines and soluble cytokine receptors with the clinicopathological features and prognosis in soft tissue sarcoma patients. Serum levels of 9 cytokines (TNF␣, IL-1ra, IL-6, IL-8, IL-10, M-CSF, G-CSF, VEGF, bFGF) and 4 free cytokine receptors (sIL-2R␣, sIL-6R, TNFRI, TNFRII) were measured by means of an enzyme-linked immunoadsorbent assay kit in 156 soft tissue sarcoma patients before the treatment and in 50 healthy controls. Serum levels of 10 cytokines and cytokine receptors were also assayed during patients' follow-up after the treatment. Significantly elevated pretreatment serum levels of 11/13 cytokines and cytokine receptors were found in sarcoma patients, as compared to healthy controls.

show abstract

Soluble Receptors for Cytokines and Growth Factors

Cited by 30 publications

References 0 publications

Cell surface expression of C1qR_P/CD93 is stabilized by O‐glycosylation

Cell surface expression of C1qR_P/CD93 is stabilized by O‐glycosylation

Relations between surface expression of the interleukin-2 receptor and release of the soluble form of the receptor in cultured mononuclear cells from patients with rheumatoid arthritis or systemic lupus erythematosus

Cytokine serum levels in soft tissue sarcoma patients: Correlations with clinico‐pathological features and prognosis

Contact Info

Product

Resources

About

Soluble Receptors for Cytokines and Growth Factors

Cited by 30 publications

References 0 publications

Cell surface expression of C1qRP/CD93 is stabilized by O‐glycosylation

Cell surface expression of C1qRP/CD93 is stabilized by O‐glycosylation

Relations between surface expression of the interleukin-2 receptor and release of the soluble form of the receptor in cultured mononuclear cells from patients with rheumatoid arthritis or systemic lupus erythematosus

Cytokine serum levels in soft tissue sarcoma patients: Correlations with clinico‐pathological features and prognosis

Contact Info

Product

Resources

About

Cell surface expression of C1qR_P/CD93 is stabilized by O‐glycosylation

Cell surface expression of C1qR_P/CD93 is stabilized by O‐glycosylation